Ambrx Biopharma Past Earnings Performance
Past criteria checks 0/6
Ambrx Biopharma's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 41% per year.
Key information
-29.9%
Earnings growth rate
-2.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -41.0% |
| Return on equity | -27.7% |
| Net Margin | -1,638.3% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Ambrx Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 4 | -67 | 31 | 36 |
| 30 Jun 23 | 6 | -60 | 26 | 32 |
| 31 Mar 23 | 6 | -71 | 25 | 36 |
| 31 Dec 22 | 7 | -78 | 23 | 41 |
| 30 Sep 22 | 6 | -87 | 21 | 59 |
| 30 Jun 22 | 5 | -91 | 20 | 63 |
| 31 Mar 22 | 7 | -76 | 19 | 56 |
| 31 Dec 21 | 7 | -68 | 18 | 53 |
| 30 Sep 21 | 10 | -54 | 16 | 42 |
| 30 Jun 21 | 12 | -40 | 13 | 31 |
| 31 Mar 21 | 13 | -28 | 10 | 25 |
| 31 Dec 20 | 14 | -17 | 8 | 19 |
| 31 Dec 19 | 10 | -20 | 8 | 25 |
Quality Earnings: AMAM is currently unprofitable.
Growing Profit Margin: AMAM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMAM is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare AMAM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMAM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: AMAM has a negative Return on Equity (-27.66%), as it is currently unprofitable.